ArticleFrontiers in medicine2026
Comorbidities in extracorporeal membrane oxygenation: a comorbidome-based analysis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Extracorporeal membrane oxygenation (ECMO) is an advanced life support modality associated with global mortality rates ranging from 48.7 to 76.38%. However, a significant knowledge gap remains regarding the specific impact of comorbidities on patient prognosis, particularly within middle-income settings in Latin America, which are characterized by substantial underreporting. Objective: To assess the relationship between comorbidities and 30-day mortality in patients receiving ECMO support, distinguishing between venoarterial (VA) and venovenous (VV) configurations. Methodology: A cross-sectional cohort study was conducted on 436 adult patients requiring ECMO support at a high-complexity institution in Colombia between 2019 and 2024. Comorbidities were assessed using the Charlson Comorbidity Index (CCI). The association with mortality was quantified using Odds Ratios (OR), and prevalence was visualized using a "Comorbidome". Results: A total of 420 patients were included, with a mean age of 43.7 (SD:13.0) years and an overall mortality rate of 30%. In the overall ECMO cohort, the most frequent comorbidities were anemia (47.7%), obesity (32.1%), and metabolic disorders (22.0%). Regarding cannulation strategies, VA configuration accounted for 36% of cases, while VV accounted for 64%. Conditions most strongly associated with overall mortality included human immunodeficiency virus (HIV) infection (OR 3.60), chronic kidney disease (OR 2.13), and hypertension (OR 1.68). Mortality associations were modality-specific: in VA-ECMO, chronic kidney disease and cancer presented the highest odds (OR 2.92), whereas in VV-ECMO, HIV infection showed the strongest association (OR 2.44). Conclusions: Pre-existing comorbidities, particularly HIV, chronic kidney disease, and hypertension, are strongly associated with mortality in this ECMO population. Identifying these conditions and their modality-specific differences is crucial for optimizing candidate selection and guiding clinical management in Latin American intensive care units.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.